Topic Hub
8 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 8 of 8 clinical reviews.
A clinical review of Aubrey de Grey's public relationship to longevity research compounds, senolytics, and the SENS framework, with peer-reviewed medical context from the HealthRX Medical Team.
Read clinical reviewHow Aubrey de Grey's confirmed longevity research advocacy compares to other public figures discussing senolytics, rapamycin, NAD+ precursors, and anti-aging interventions, with clinical context from the HealthRX Medical Team.
Read clinical reviewA clinical look at Aubrey de Grey's public longevity advocacy, documented self-experimentation statements, and the science behind the SENS framework and senolytic compounds he champions.
Read clinical reviewAubrey de Grey has spent decades advocating for longevity interventions. The HealthRX Medical Team examines what clinical science says about stopping or maintaining senolytic and longevity-research compounds.
Read clinical reviewAubrey de Grey has spoken openly about longevity compounds and their side effects. The HealthRX Medical Team matches his public statements against peer-reviewed adverse-event data.
Read clinical reviewWhat Aubrey de Grey's public advocacy for SENS and senolytics teaches everyday patients about longevity medicine, realistic expectations, and the current clinical evidence.
Read clinical reviewAubrey de Grey has publicly discussed personal experimentation with longevity compounds in podcast interviews. Here is what the SENS framework, senolytics, and related interventions would actually cost an ordinary patient navigating insurance and pharmacy options in 2024.
Read clinical reviewThe HealthRX Medical Team breaks down the longevity compounds Aubrey de Grey has publicly discussed, translating SENS research into real clinical context around senolytics, NAD+ precursors, and rapamycin.
Read clinical review